Drug Trial Radar · NCT00769067
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen
Last checked: Nov 20, 2026Latest source record: Oct 7, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
188
Actual
Start
Nov 2008
Primary completion
Oct 2010
Study completion Aug 2014
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 8, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one of these drugs, and followed for efficacy and tolerance of each.
Conditions
- Non-small Cell Lung Cancer
Interventions
ErlotinibDrug
Continuous oral dosing at 150 mg daily.
PF-00299804Drug
Continuous oral dosing at 45mg daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Baseline until disease progression or death, assessed at Cycle 2, 3, 4, 5, 6, thereafter every other cycle up to end of treatment (121 weeks), followed by every 8 weeks >284 weeks
Locations
59 sites in 12 countries. Site status is shown where the registry gives one.
Northwest Alabama Cancer Center
Muscle Shoals, Alabama
Agajanian Institute of Oncology and Hematology
Montebello, California
Bridgeport Hospital
Bridgeport, Connecticut
Wittingham Cancer Center @ Norwalk Hospital
Norwalk, Connecticut
Medical Oncology & Hematology, P.C.
Waterbury, Connecticut
Winship Cancer Institute at Grady Health Systems
Atlanta, Georgia
Winship Cancer Institute, Emory University
Atlanta, Georgia
Winship Cancer Institute at Emory University
Atlanta, Georgia
Winship Cancer Institute of Emory University
Atlanta, Georgia
Winship Cancer Institute, Emory University
Atlanta, Georgia
Augusta Oncology Associates, P.C.
Augusta, Georgia
Augusta Oncology Associates, PC
Augusta, Georgia
John B. Amos Cancer Center
Columbus, Georgia
Georgia Cancer Specialists
Decatur, Georgia
The Longstreet Cancer Center
Gainesville, Georgia
Central Georgia Cancer Care, P.C.
Macon, Georgia
Northwest Georgia Oncology Center
Marietta, Georgia
Central Georgia Cancer Care, P.C.
Warner Robins, Georgia
Kootenai Cancer Center at Post Falls
Post Falls, Idaho
Kootenai Cancer Center
Post Falls, Idaho
Midwestern Regional Medical Center
Zion, Illinois
Center for Blood and Cancer Disorders
Bethesda, Maryland
Associates in Oncology/Hematology, PC
Rockville, Maryland
University of Minnesota Cancer Center
Minneapolis, Minnesota
The West Clinic
Memphis, Tennessee
Oncology/Hematology Associates
Clarksburg, West Virginia
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
St. Vincent's Hospital
Fitzroy, Victoria, Australia
The Andrew Love Cancer Centre,
Geelong, Victoria, Australia
Border Medical Oncology
Wodonga, Victoria, Australia
Irmandade da Santa Casa de Misericordia de Porto Alegre (ISCMPA) - Hospital Santa Rita
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Sao Lucas da PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
FUNDACAO PIO XII Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira - ICESP
São Paulo, São Paulo, Brazil
BC Cancer Agency - Vancouver Centre
Vancouver, British Columbia, Canada
Royal Victoria Hospital
Barrie, Ontario, Canada
RSM Durham Regional Cancer Centre - Lakeridge Health Oshawa
Oshawa, Ontario, Canada
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
Department of Clinical Oncology
Shatin, New Territories, Hong Kong
Department of Clinical Oncology, Tuen Mun Hospital
Tuenmen, New Territories, Hong Kong
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.